HGH dosage: what the labels and the trials used

Reviewed 14 sourcesPublished by PepVault

HGH dosage on the FDA labels: 0.2 mg (0.6 IU) a day to start in adult deficiency, up to 6 or 8 mg in HIV wasting and short bowel, with IU and side effects.

A silver-haired man in a navy sleeveless top doing a push-up on a mat on a deck
Last reviewed
Sources
14
Questions
7
Compounds
3

The short answer

The FDA labels start adults with growth hormone deficiency on about 0.2 mg of somatropin a day (0.6 IU, at 3 IU per mg), raised every 1 to 2 months by IGF-1. Their weight-based ceilings come to 0.9 to 1.3 mg (2.7 to 3.8 IU) a day at 80 kg. The HIV-wasting and short-bowel labels go up to 6 and 8 mg (18 and 24 IU) a day.

  • Adult replacement starts near 0.2 mg (0.6 IU) a day and is adjusted to IGF-1, not to a fixed number.
  • Labels write the dose in mg; the labels' own figures put 1 mg at 3 IU.
  • The HIV-wasting dose (0.1 mg/kg, up to 6 mg a day) is 30 times the adult starting dose.
  • Joint pain and swelling rose step by step with the dose in the Serostim trial.

Every number checked at its primary source · · 14 sources · How we research

Evidence: FDA labels built on randomized trials in adults with growth hormone deficiency, HIV wasting and short bowel syndrome, plus a systematic review of randomized trials in 18 small study populations of healthy older adults.

A silver-haired man in a navy sleeveless top doing a push-up on a mat on a deck

How do the HGH labels dose growth hormone?

In milligrams of somatropin, the drug name for recombinant human growth hormone (pepvault.app/glossary/growth-hormone), given as one injection under the skin each day. Five daily somatropin labels on DailyMed (Genotropin, Omnitrope, Humatrope, Norditropin and Zomacton) carry the same flat starting dose for adults with growth hormone deficiency: about 0.2 mg a day, within a range of 0.15 to 0.3 mg, without regard to body weight12345. From there the dose goes up by about 0.1 to 0.2 mg a day every 1 to 2 months, by how the person responds and by their IGF-1, the blood marker that growth hormone raises in the liver12.

Each label also gives a weight-based option, and here they differ. Genotropin and Omnitrope start at no more than 0.04 mg/kg a week, split into daily shots, and go no higher than 0.08 mg/kg a week12. Humatrope and Zomacton start at 0.006 mg/kg a day with a ceiling of 0.0125 mg/kg35; Norditropin starts at 0.004 mg/kg a day with a ceiling of 0.016 mg/kg4. Humatrope, Norditropin and Zomacton say the weight-based route is not recommended for people with obesity345.

PepVault logs each growth hormone dose in IU or in mg, whichever your prescription is written in, so your record reads the way your label does. Log it in PepVault

One newer product is dosed weekly. Sogroya (somapacitan), a long-acting growth hormone, starts adults at 1.5 mg once a week, rises by 0.5 to 1.5 mg every 2 to 4 weeks, and stops at 8 mg a week; adults 65 and over start at 1 mg6. It is a modified molecule, so its milligrams do not line up one to one with daily somatropin's.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each growth hormone dose in IU or in mg, whichever your prescription is written in, so your record reads the way your label does.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How many IU is an HGH dose in mg?

Three IU per milligram, by the labels' own figures. An IU (international unit, pepvault.app/glossary/iu) measures a hormone by its effect rather than its weight. Humatrope's cartridges hold 6 mg (18 IU), 12 mg (36 IU) and 24 mg (72 IU)3; Serostim's animal studies list 0.033 mg/kg as 0.1 IU/kg7; Zorbtive's 4 mg vial held "approximately 12 IU"8. One line in Humatrope's own label gives 0.1 mg/kg as 0.27 IU/kg, a ratio of 2.7 IU per mg and the one place a label departs from 33. Today's US labels write every dose in mg; IU is the older unit, and many papers and people still count in it. The PepVault dose converter does the arithmetic at 3 IU per mg (pepvault.app/tools/peptide-dosage-calculator).

The table puts each label's and trial's numbers side by side, worked out for one adult of 80 kg (176 lb) so they can be compared. It is arithmetic on published doses, not a dose for anyone.

Label or trialDose as writtenFor 80 kg, per dayIn IU, per day
Adult deficiency, flat start (five labels)123450.2 mg a day (0.15 to 0.3)0.2 mg0.6 IU (0.45 to 0.9)
Genotropin, Omnitrope, by weight120.04 up to 0.08 mg/kg a week0.46 up to 0.91 mg1.4 up to 2.7 IU
Humatrope, Zomacton, by weight350.006 up to 0.0125 mg/kg a day0.48 up to 1.0 mg1.4 up to 3.0 IU
Norditropin, by weight40.004 up to 0.016 mg/kg a day0.32 up to 1.28 mg1.0 up to 3.8 IU
Healthy older adults, pooled trials (starting dose)9Mean 14 µg/kg a day1.1 mg3.4 IU
Older men, Rudman and Papadakis10110.03 mg/kg three times a week1.0 mg (2.4 mg a shot)3.1 IU (7.2 IU a shot)
Serostim, HIV wasting70.1 mg/kg a day, up to 6 mg6 mg18 IU
Zorbtive, short bowel, 4 weeks80.1 mg/kg a day, up to 8 mg8 mg24 IU

Per-day figures for the three-times-a-week trials are the weekly total divided by seven. The weight-based rows run from each label's starting dose to its ceiling.

How is an HGH dose adjusted on the label?

By IGF-1 and by side effects, in small steps, with the prescriber making each change. The labels' rules for adults are short135:

  • The daily dose goes up by about 0.1 to 0.2 mg every 1 to 2 months, by clinical response and IGF-1.
  • It comes down when side effects appear or IGF-1 rises above the normal range for the person's age and sex.
  • Older adults start lower and step up more slowly, since they are more prone to side effects.
  • Women with normal estrogen, and women taking estrogen by mouth, may need more than men.

Maintenance doses "vary considerably from person to person, and between male and female patients", in Genotropin's words1. That is why the labels steer by a blood test rather than a target number: the same 0.5 mg can put one adult's IGF-1 mid-range and another's above it. On the weekly Sogroya, the IGF-1 sample is drawn 3 to 4 days after a dose6. More on the condition itself: pepvault.app/conditions/growth-hormone-deficiency.

Set a dose time, bedtime included, and PepVault reminds you if that day's dose is not logged yet; its doctor's report puts your log in front of your prescriber when the next IGF-1 result comes back. Set reminders in PepVault

What dose did the HIV-wasting and short-bowel labels use?

Far above adult replacement: 6 mg a day is 30 times the adult starting dose. Serostim, approved for HIV-associated wasting, is dosed at 0.1 mg/kg once daily at bedtime, up to 6 mg: 6 mg above 55 kg, 5 mg at 45 to 55 kg, 4 mg at 35 to 45 kg7. In its first trial (178 people, 12 weeks), weight rose 1.6 kg more than on placebo and lean body mass 3.1 kg more, and treadmill work output went up 13%7.

The second Serostim trial ran the same 0.1 mg/kg either daily or every other day. Every other day caused fewer side effects and a similar gain in work output, so the label tells prescribers to consider it for people at higher risk, such as those with glucose intolerance7. About 23% on the daily dose and 11% on alternate days needed a dose cut7.

Zorbtive, for short bowel syndrome, used about 0.1 mg/kg a day, up to 8 mg, for 4 weeks alongside a specialized diet; its label says longer use "has not been adequately studied"8. People on it needed less intravenous nutrition each week than those on placebo. Drugs@FDA lists its 4, 5 and 6 mg vials as discontinued and the 8.8 mg vial as still prescription14; DailyMed carries no current Zorbtive label.

What did HGH trials in healthy older adults use, and what did they find?

Doses near the top of adult replacement, and a swap of about 2 kg of fat for 2 kg of lean mass. A Stanford systematic review pooled the randomized trials in healthy adults with a mean age of 50 or more (18 study populations, 220 people who completed growth hormone, mean age 69)9. The mean starting dose was 14 µg/kg a day, for an average of 27 weeks. Fat mass fell 2.1 kg and lean mass rose 2.1 kg against no treatment; body weight did not change, and neither did bone density9.

The interest began with Rudman's 1990 study: 21 healthy men aged 61 to 81 took part, and the 12 treated got about 0.03 mg/kg three times a week for six months. Their IGF-1 rose into the 500 to 1,500 U/L range of young adults, lean mass went up 8.8% and fat mass down 14.4%10. Papadakis repeated the dose in 52 men over 69 against placebo. Lean mass rose 4.3% and fat fell 13.1%, but knee strength, grip strength and endurance did not improve, and 26% of the men on growth hormone needed a lower dose11.

Blackman's trial in 131 women and men aged 65 to 88 started at 30 µg/kg three times a week and cut it to 20 µg/kg. Men gained 3.1 kg of lean mass on growth hormone alone and 4.3 kg with testosterone; only the combination nudged men's strength up, by a borderline 13.5 kg12. The review's conclusion was plain: small changes in body composition, more side effects, and no case for growth hormone as an anti-aging therapy9.

Do HGH side effects rise with the dose?

Yes, and the second Serostim trial shows it in steps. Most of these effects come from fluid the body holds on to, and the labels describe them as "usually transient and dose dependent"1.

Side effect (second Serostim trial, 12 weeks)Placebo0.1 mg/kg every other day0.1 mg/kg daily
Joint pain11.3%24.5%36.4%
Muscle pain11.7%17.9%30.4%
Swelling of hands or feet2.8%11.3%26.1%
Breast tissue growth in men (gynecomastia)0.4%3.5%5.5%

Swelling shows up at replacement doses too. In Norditropin's six-month placebo trial in adults, swelling of the arms or legs (peripheral edema) affected 42% against 8% on placebo, tingling 11% against 6%, and 5% developed type 2 diabetes against none4. In the short-bowel trial at about 0.1 mg/kg a day, 94% had swelling of the arms or legs and 69 to 81% a swollen face8. In Blackman's older adults, 18 men on growth hormone developed diabetes or glucose intolerance against 7 without it12. The labels ask for glucose checks in everyone on somatropin1. When a label lowers the dose, it is usually for this group: swelling, joint pain, carpal tunnel and glucose7.

The same 0.1 mg/kg a day went badly in the critically ill. In two intensive-care trials, adults recovering from surgery, trauma or respiratory failure got about 0.1 mg/kg a day; deaths in hospital were 39% and 44% against 20% and 18% on placebo13. Every current growth hormone label we read lists acute critical illness as a reason not to start it1234567. Genotropin's label also lists active cancer; active proliferative or severe non-proliferative diabetic retinopathy; children with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe breathing problems, after reports of sudden death; children whose growth plates have closed; and allergy to somatropin or the product's other ingredients1. See also pepvault.app/peptides/hgh/side-effects.

When to get help A new headache with changes in vision, nausea or vomiting, most often in the first eight weeks, is what the labels ask you to report to your prescriber13.

Is HGH approved for anti-aging or building muscle?

No. Somatropin is approved in the US for growth hormone deficiency in adults and children, for several childhood growth disorders, for HIV wasting and for short bowel syndrome178. The Stanford review notes that its use as an anti-aging therapy is not FDA-approved and that distributing it for that purpose is illegal in the United States9. The country-by-country picture: pepvault.app/peptides/hgh/legal-status.

For the compounds that raise the body's own growth hormone instead, the same kind of label-and-trial read exists for sermorelin, and tesamorelin has its own approved label for belly fat in HIV. The full HGH page, with its half-life, is pepvault.app/peptides/hgh; the dose guide is pepvault.app/lab/dosage/hgh; side-by-side comparisons start at pepvault.app/peptides/compare/hgh-vs-sermorelin.

Track it in the app

Sources

  1. Genotropin (somatropin) prescribing information. Pfizer. DailyMed, 2026. dailymed.nlm.nih.gov
  2. Omnitrope (somatropin) prescribing information. Sandoz. DailyMed, 2025. dailymed.nlm.nih.gov
  3. Humatrope (somatropin) prescribing information. Eli Lilly. DailyMed, 2026. dailymed.nlm.nih.gov
  4. Norditropin (somatropin) prescribing information. Novo Nordisk. DailyMed, 2025. dailymed.nlm.nih.gov
  5. Zomacton (somatropin) prescribing information. Ferring. DailyMed, 2026. dailymed.nlm.nih.gov
  6. Sogroya (somapacitan-beco) prescribing information. Novo Nordisk. DailyMed, 2026. dailymed.nlm.nih.gov
  7. Serostim (somatropin) prescribing information. EMD Serono. DailyMed, 2026. dailymed.nlm.nih.gov
  8. Zorbtive (somatropin) prescribing information. Serono. FDA, 2003. accessdata.fda.gov
  9. Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007. PubMed 17227934
  10. Rudman D et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990. PubMed 2355952
  11. Papadakis MA et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med. 1996. PubMed 8633830
  12. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002. PubMed 12425705
  13. Takala J et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999. PubMed 10477776
  14. Drugs@FDA: Zorbtive (BLA 021597), marketing status. accessdata.fda.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo